A quest to optimize the clinical pharmacology of tuberculosis and human immunodeficiency virus drug treatment

Daskapan, A., 2018, [Groningen]: Rijksuniversiteit Groningen. 178 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard


  • Title and contents

    Final publisher's version, 143 KB, PDF document

  • Chapter 1

    Final publisher's version, 207 KB, PDF document

  • Chapter 2

    Final publisher's version, 730 KB, PDF document

  • Chapter 3

    Final publisher's version, 260 KB, PDF document

  • Chapter 4

    Final publisher's version, 244 KB, PDF document

  • Chapter 5

    Final publisher's version, 341 KB, PDF document

    Embargo ends: 01/01/9999

  • Chapter 5 Publisher's version

    Final publisher's version, 1 MB, PDF document

  • Chapter 6

    Final publisher's version, 381 KB, PDF document

  • Chapter 7

    Final publisher's version, 253 KB, PDF document

  • Chapter 8

    Final publisher's version, 202 KB, PDF document

  • Chapter 9

    Final publisher's version, 203 KB, PDF document

  • Summary

    Final publisher's version, 127 KB, PDF document

  • Dankwoord

    Final publisher's version, 101 KB, PDF document

  • Curriculum Vitae

    Final publisher's version, 69 KB, PDF document

  • Publication list

    Final publisher's version, 513 KB, PDF document

  • Complete pdf

    Final publisher's version, 2 MB, PDF document

    Embargo ends: 01/01/9999

  • Propositions

    Final publisher's version, 317 KB, PDF document

  • Alper Daskapan
TB currently is the number one killer among infectious diseases, with a sad record of 1.7 million deaths in 2016 alone. HIV infection is the most important risk factor for TB. Patients with TB/HIV co-infection suffer from drug-drug interactions, they have a high pill burden and they have to adjust their lifestyles radically to cure or inhibit their infection. In addition they also have an increased risk for an unsuccessful treatment due to a possibly altered absorption, metabolism or excretion of drugs (due to naturally occurring variation in pharmacokinetics). This thesis focuses on the optimization of the pharmaceutical treatment of TB in people with both an HIV and TB infection and also on the optimal use of the antiretroviral drug darunavir.
We provided insight on the effect of HIV-infection on the exposure to first-line TB drugs by assessing published literature. Due to the complexity of the TB bacteria people with TB have to be treated 6 months with TB drugs. In daily practice however, a proportion of the patients is treated longer than 6 months. We therefore also studied the potential risk factors contributing to a prolonged TB treatment. Further, we provided insight in the complexity of the treatment of people with TB/HIV co-infection by describing the treatment of individual patient.
In addition, we have also developed methods, such as a laboratory test and an algorithm, which could contribute to customized darunavir therapy. We also investigated the food intake of people using darunavir in order to promote healthy food intake.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date21-Nov-2018
Place of Publication[Groningen]
Print ISBNs978-94-034-1162-0
Electronic ISBNs978-94-034-1161-3
Publication statusPublished - 2018

Download statistics

No data available

ID: 66845409